Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bastard

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?M Bastard, E Sanchez-Padilla, A Hayrapetyan, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 22, 2016
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort studyM Bonnet, M Bastard, P du Cros, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and GeorgiaC Hewison, M Bastard, N Khachatryan, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TBC Zeng, C D Mitnick, C Hewison, et al.
IJTLD Open|May 14, 2025
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TBC Zeng, M A Hernán, L Trevisi, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 26, 2023
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implicationsM L Rich, U Khan, C Zeng, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?M Bastard, E Sanchez-Padilla, A Hayrapetyan, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 22, 2016
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort studyM Bonnet, M Bastard, P du Cros, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and GeorgiaC Hewison, M Bastard, N Khachatryan, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2023
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TBC Zeng, C D Mitnick, C Hewison, et al.
IJTLD Open|May 14, 2025
Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TBC Zeng, M A Hernán, L Trevisi, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 26, 2023
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implicationsM L Rich, U Khan, C Zeng, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Introducing new and repurposed TB drugs: the endTB experienceK J Seung, U Khan, F Varaine, et al.
Pageof 2